Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
grade F 16.21 -0.86% -0.14
MGNX closed down 0.86 percent on Thursday, April 18, 2019, on 37 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MGNX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup -0.86%
Reversal New Lows Setup Bearish Swing Setup -0.86%
Slingshot Bearish Bearish Swing Setup -0.86%
Lower Bollinger Band Walk Weakness -0.86%
Outside Day Range Expansion -0.86%

Older signals for MGNX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Treatment Of Cancer Antibodies Immune System Monoclonal Antibodies Autoimmune Diseases Antibody Technology Platforms Novel Cancer
Is MGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.32
52 Week Low 9.87
Average Volume 1,124,966
200-Day Moving Average 18.4337
50-Day Moving Average 19.6582
20-Day Moving Average 18.3185
10-Day Moving Average 17.813
Average True Range 0.9052
ADX 19.06
+DI 14.3361
-DI 34.543
Chandelier Exit (Long, 3 ATRs ) 17.4095
Chandelier Exit (Short, 3 ATRs ) 18.4856
Upper Bollinger Band 20.444
Lower Bollinger Band 16.193
Percent B (%b) 0.0
BandWidth 23.206049
MACD Line -0.6311
MACD Signal Line -0.342
MACD Histogram -0.2891
Fundamentals Value
Market Cap 596.49 Million
Num Shares 36.8 Million
EPS -4.19
Price-to-Earnings (P/E) Ratio -3.87
Price-to-Sales 56.93
Price-to-Book 2.96
PEG Ratio 0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.44
Resistance 3 (R3) 17.43 17.01 17.24
Resistance 2 (R2) 17.01 16.70 17.02 17.17
Resistance 1 (R1) 16.61 16.50 16.40 16.62 17.10
Pivot Point 16.19 16.19 16.09 16.20 16.19
Support 1 (S1) 15.79 15.88 15.58 15.80 15.32
Support 2 (S2) 15.37 15.68 15.38 15.25
Support 3 (S3) 14.97 15.37 15.19
Support 4 (S4) 14.98